Sangamo Therapeutics Stock Price, News & Analysis (NASDAQ:SGMO) $0.39 +0.02 (+5.38%) (As of 11/28/2023 ET) Add Compare Share Share Today's Range$0.36▼$0.4050-Day Range$0.30▼$0.8552-Week Range$0.29▼$3.76Volume921,835 shsAverage Volume2.02 million shsMarket Capitalization$69.47 millionP/E RatioN/ADividend YieldN/APrice Target$4.68 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Sangamo Therapeutics MarketRank™ Stock AnalysisAnalyst RatingHold2.29 Rating ScoreUpside/Downside1,093.5% Upside$4.68 Price TargetShort InterestHealthy5.81% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.62Based on 3 Articles This WeekInsider TradingSelling Shares$3 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.82) to ($0.53) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.19 out of 5 starsMedical Sector382nd out of 949 stocksBiological Products, Except Diagnostic Industry61st out of 161 stocks 3.1 Analyst's Opinion Consensus RatingSangamo Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.29, and is based on 3 buy ratings, 3 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $4.68, Sangamo Therapeutics has a forecasted upside of 1,093.5% from its current price of $0.39.Amount of Analyst CoverageSangamo Therapeutics has only been the subject of 4 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted5.81% of the outstanding shares of Sangamo Therapeutics have been sold short.Short Interest Ratio / Days to CoverSangamo Therapeutics has a short interest ratio ("days to cover") of 4.9.Change versus previous monthShort interest in Sangamo Therapeutics has recently decreased by 11.04%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldSangamo Therapeutics does not currently pay a dividend.Dividend GrowthSangamo Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SGMO. Previous Next 3.1 News and Social Media Coverage News SentimentSangamo Therapeutics has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.86 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Sangamo Therapeutics this week, compared to 2 articles on an average week.Search Interest8 people have searched for SGMO on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.MarketBeat Follows16 people have added Sangamo Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 78% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Sangamo Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,000,000.00 in company stock.Percentage Held by InsidersOnly 3.00% of the stock of Sangamo Therapeutics is held by insiders.Percentage Held by Institutions59.81% of the stock of Sangamo Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Sangamo Therapeutics are expected to grow in the coming year, from ($0.82) to ($0.53) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Sangamo Therapeutics is -0.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sangamo Therapeutics is -0.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSangamo Therapeutics has a P/B Ratio of 0.22. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Sangamo Therapeutics Stock (NASDAQ:SGMO)Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Brisbane, California.Read More SGMO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SGMO Stock News HeadlinesNovember 26, 2023 | americanbankingnews.comSangamo Therapeutics (NASDAQ:SGMO) Receives New Coverage from Analysts at StockNews.comNovember 25, 2023 | americanbankingnews.comSangamo Therapeutics, Inc. (NASDAQ:SGMO) Given Consensus Rating of "Hold" by AnalystsNovember 28, 2023 | RYSE INC. (Ad)Secure your stake in the Smart Home industry.Last chance to invest in RYSE – the shade automation technology launching in over 100 Best Buy stores this month.November 18, 2023 | americanbankingnews.comSangamo Therapeutics (NASDAQ:SGMO) Now Covered by Analysts at StockNews.comNovember 8, 2023 | msn.comTruist Securities Downgrades Sangamo Therapeutics (SGMO)November 6, 2023 | msn.comWells Fargo Downgrades Sangamo Therapeutics (SGMO)November 6, 2023 | msn.comWells Fargo downgrades Sangamo, cites removal of key year-end catalystNovember 6, 2023 | markets.businessinsider.comWhere Sangamo Therapeutics Stands With AnalystsNovember 28, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comNovember 6, 2023 | markets.businessinsider.comWhat 8 Analyst Ratings Have To Say About Sangamo TherapeuticsNovember 3, 2023 | msn.comRBC Capital downgrades Sangamo as biotech moves to save cashNovember 3, 2023 | msn.comRBC Capital Downgrades Sangamo Therapeutics (SGMO)November 3, 2023 | finance.yahoo.comSangamo Therapeutics, Inc. (NASDAQ:SGMO) Q3 2023 Earnings Call TranscriptNovember 3, 2023 | markets.businessinsider.comWhat To Know About RBC Capital's Downgrade of Sangamo TherapeuticsNovember 2, 2023 | msn.comBiotech company Sangamo Therapeutics laying off 40% of workers, closing HQNovember 2, 2023 | msn.comSangamo Therapeutics (SGMO) Price Target Increased by 9.38% to 6.71November 1, 2023 | finance.yahoo.comSangamo Therapeutics Announces Strategic Update and Reports Third Quarter 2023 Financial ResultsNovember 1, 2023 | finance.yahoo.comSangamo Therapeutics Inc (SGMO) Announces Q3 2023 Financial Results and Strategic UpdateNovember 1, 2023 | markets.businessinsider.comSangamo Therapeutics earnings preview: what Wall Street is expectingOctober 26, 2023 | finance.yahoo.comSangamo Therapeutics (SGMO) May Report Negative Earnings: Know the Trend Ahead of Q3 ReleaseOctober 25, 2023 | finance.yahoo.comSangamo Therapeutics Announces Third Quarter 2023 Conference Call and WebcastOctober 24, 2023 | businesswire.comSangamo Therapeutics to Present Pre-Clinical Data Showcasing Its Epigenetic Regulation for Neurology and CAR-Treg Research at the 30th Annual Congress of the European Society ...October 24, 2023 | finance.yahoo.comSangamo Therapeutics to Present Pre-Clinical Data Showcasing Its Epigenetic Regulation for Neurology and CAR-Treg Research at the 30th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)September 29, 2023 | benzinga.comSangamo Therapeutics 10% Owner Sold $3.00M In Company StockSeptember 8, 2023 | msn.comSangamo Therapeutics: Recent Updates Bolster My Long-Term ConvictionSeptember 4, 2023 | finance.yahoo.comRecent uptick might appease Sangamo Therapeutics, Inc. (NASDAQ:SGMO) institutional owners after losing 82% over the past yearSeptember 2, 2023 | finance.yahoo.comUntapped Potential: 3 Stocks Tackling the Toughest Rare DiseasesSee More Headlines Receive SGMO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sangamo Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/01/2023Today11/28/2023Fiscal Year End12/31/2023Next Earnings (Estimated)2/28/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:SGMO CUSIP80067710 CIK1001233 Webwww.sangamo.com Phone(510) 970-6000Fax510-236-8951Employees478Year Founded1995Price Target and Rating Average Stock Price Target$4.68 High Stock Price Target$10.00 Low Stock Price Target$1.00 Potential Upside/Downside+1,093.5%Consensus RatingHold Rating Score (0-4)2.29 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($1.45) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-192,280,000.00 Net Margins-123.88% Pretax Margin-126.13% Return on Equity-61.40% Return on Assets-39.63% Debt Debt-to-Equity RatioN/A Current Ratio3.04 Quick Ratio3.04 Sales & Book Value Annual Sales$111.30 million Price / Sales0.62 Cash FlowN/A Price / Cash FlowN/A Book Value$1.80 per share Price / Book0.22Miscellaneous Outstanding Shares177,350,000Free Float172,027,000Market Cap$69.47 million OptionableOptionable Beta1.12 Social Links 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Alexander D. Macrae Ch.B (Age 60)M.B., MRCP, Ph.D., CEO, President & Director Comp: $1.17MMs. Prathyusha Duraibabu CPA (Age 44)M.B.A., Senior VP, CFO & Principal Accounting Officer Comp: $628.08kMr. D. Mark McClung (Age 60)Executive VP & COO Comp: $710.3kDr. Jason D. Fontenot Ph.D. (Age 53)Senior VP & Chief Scientific Officer Comp: $682.76kPhillip RamseyHead of Technical OperationsMs. Aron FeingoldHead of Corporate Communications & Investor Relations OfficerMr. Scott B. Willoughby (Age 48)Senior VP, General Counsel & Corporate Secretary Ms. Whitney JonesChief People OfficerDr. Nathalie Dubois-Stringfellow Ph.D. (Age 61)Senior VP & Chief Development Officer Dr. Lisa Rojkjaer M.D. (Age 57)Chief Medical Officer More ExecutivesKey CompetitorsCurisNASDAQ:CRISCidara TherapeuticsNASDAQ:CDTXaTyr PharmaNASDAQ:LIFEJasper TherapeuticsNASDAQ:JSPRCompugenNASDAQ:CGENView All CompetitorsInsiders & InstitutionsGraham Capital Management L.P.Bought 28,354 shares on 11/22/2023Ownership: 0.054%Jacobs Levy Equity Management Inc.Bought 195,734 shares on 11/17/2023Ownership: 0.228%Public Employees Retirement System of OhioSold 314,669 shares on 11/16/2023Ownership: 0.028%GSA Capital Partners LLPSold 247,223 shares on 11/15/2023Ownership: 0.316%Ameriprise Financial Inc.Bought 83,010 shares on 11/15/2023Ownership: 0.047%View All Insider TransactionsView All Institutional Transactions SGMO Stock Analysis - Frequently Asked Questions Should I buy or sell Sangamo Therapeutics stock right now? 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Sangamo Therapeutics in the last twelve months. There are currently 1 sell rating, 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" SGMO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SGMO, but not buy additional shares or sell existing shares. View SGMO analyst ratings or view top-rated stocks. What is Sangamo Therapeutics' stock price target for 2024? 7 brokers have issued 1 year price objectives for Sangamo Therapeutics' stock. Their SGMO share price targets range from $1.00 to $10.00. On average, they predict the company's stock price to reach $4.68 in the next twelve months. This suggests a possible upside of 1,093.5% from the stock's current price. View analysts price targets for SGMO or view top-rated stocks among Wall Street analysts. How have SGMO shares performed in 2023? Sangamo Therapeutics' stock was trading at $3.14 at the start of the year. Since then, SGMO shares have decreased by 87.5% and is now trading at $0.3917. View the best growth stocks for 2023 here. When is Sangamo Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 28th 2024. View our SGMO earnings forecast. How were Sangamo Therapeutics' earnings last quarter? Sangamo Therapeutics, Inc. (NASDAQ:SGMO) posted its quarterly earnings data on Wednesday, November, 1st. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.33) by $0.01. The biopharmaceutical company earned $9.40 million during the quarter, compared to analyst estimates of $10.17 million. Sangamo Therapeutics had a negative net margin of 123.88% and a negative trailing twelve-month return on equity of 61.40%. What ETFs hold Sangamo Therapeutics' stock? ETFs with the largest weight of Sangamo Therapeutics (NASDAQ:SGMO) stock in their portfolio include Kelly CRISPR & Gene Editing Technology ETF (XDNA) and Morningstar US Small Growth (MSGR).Global X Genomics & Biotechnology ETF (GNOM). What is Sandy Macrae, M.B., Ch.B., Ph.D.'s approval rating as Sangamo Therapeutics' CEO? 10 employees have rated Sangamo Therapeutics Chief Executive Officer Sandy Macrae, M.B., Ch.B., Ph.D. on Glassdoor.com. Sandy Macrae, M.B., Ch.B., Ph.D. has an approval rating of 89% among the company's employees. What other stocks do shareholders of Sangamo Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Sangamo Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU), CRISPR Therapeutics (CRSP), Novavax (NVAX), Gilead Sciences (GILD), Brainstorm Cell Therapeutics (BCLI), Editas Medicine (EDIT), Netflix (NFLX) and Intel (INTC). Who are Sangamo Therapeutics' major shareholders? Sangamo Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Acadian Asset Management LLC (1.65%), Charles Schwab Investment Management Inc. (0.67%), UBS Group AG (0.42%), Mirae Asset Global Investments Co. Ltd. (0.38%), GSA Capital Partners LLP (0.32%) and Jacobs Levy Equity Management Inc. (0.23%). Insiders that own company stock include Biogen Inc, Gary Loeb, John Markels, Rolf Andrew Ramelmeier and Saira Ramasastry. View institutional ownership trends. How do I buy shares of Sangamo Therapeutics? Shares of SGMO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:SGMO) was last updated on 11/28/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sangamo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.